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Figure 1. A schematic
representation of human
papilloma virus oncoproteins
E6 and E7 integration leading
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Tumour markers for oropharyngeal cancers
Head and neck cancers (HNC) are a globally prevalent
malignancy. Despite the efforts of reducing several
known etiological factors such as smoking and
drinking to lower the incidence of HNC at the
population level, the incidence of oropharyngeal
cancers (OPC) is on the rise. OPC is caused by human
papillomavirus (HPV) and most prevalent in a
younger age group. This review critically examines
the epidemiology, biology and laboratory detection of
OPC and provides future insights into combating this
debilitating disease.
by X. C. Sun, P. Tran and Dr C. Punyadeera
 
Introduction
Head and neck cancers (HNC) are the sixth most
prevalent neoplasm in the world with approximately 650
000 cases diagnosed each year [1–5]. Oral and
oropharyngeal squamous cell carcinomas (OSCC &
OPSCC) together constitute 90% of malignancies in the
head and neck region. Several known traditional etiological factors such as tobacco and
alcohol use are recognized in the development of these cancers. More recently, human
papillomavirus (HPV) infection is recognized as an additional risk factor for the
development of a subset of HNCs, mainly OPSCC [6].
In recent decades, the overall incidence of HNC caused by smoking and alcohol is on the
decline. In contrast, HPV+ve OPSCC is on the rise. In developed countries such as the
United States of America, the incidence of HPV+ve OPSCC is escalating, with predictions
that more than 50% of patients will be HPV+ve by 2030 [7]. Interestingly, patients who
are HPV+ve OPSCC are relatively younger than HPV-ve HNC patients and are therefore
less likely to have any history of chronic or excessive alcohol or tobacco use but are more
likely to engage in social habits that increase the likelihood of HPV transmission (oral
sex). The clear distinction between HPV+ve OPSCC and HPV-ve cases provides multiple
downstream inputs that can be applied into clinical treatment modalities. Conversely, it
provides an exciting opportunity for the development of early diagnostic and screening
methods to combat HNC at a population level through prevention strategies.
HPV+ve OPSCC are both clinically and biologically distinct tumour entities compared with
HPV-ve counterparts. Classically, HPV+ve OPSCC patients present with a molecular profile
that includes retinoblastoma (pRB) pathway inactivation, p53 degradation and p16
upregulation. Clinically, HPV+ve OPSCC patients often present with smaller primary
tumours but more advanced nodal disease, similar rates of metastasis and differing
patterns of metastasis [8, 9]. In addition, patients with HPV+ve tumours have better
prognosis with 5-year survival at 75% (c.f. 25% for HPV-ve patients). There are a
number of techniques for the diagnosis and detection of HPV+ve OPSCC, including
histopathology, polymerase chain reaction (PCR) and immunohistochemistry (IHC).
Biology
Upon integration of HPV DNA into the host genome, E6 and E7 viral oncoproteins activate
a number of pathways within the host cell. The primary molecular target of E7 is the Rb
protein and the E7 viral oncoprotein reprogrammes terminally differentiated epithelial
cells to re-enter the cell cycle. E7 disrupts the Rb–E2F complex leading to the release of
E2F, subsequently resulting in cyclin A and E activation and entry of the cell into S
phase. As a consequence p16 is overexpressed [10, 11]. The E6-associated protein (E6-
AP) is a specific ubiquitin-ligase that binds to the viral E6 oncoprotein, resulting in p53
degradation. E6 and E7 have also been shown to interfere with growth inhibitory
cytokines [such as tumour necrosis factor-α (TNFα)] and to disrupt the mitochondrial
apoptotic pathway by interfering with pro-apoptotic BAK and BAX [10]. E6 and E7 alone
are insufficient to cause malignant cell transformation; however, due to their interference
with proliferation checkpoints and apoptotic pathways, it is certain that the accumulation
and damaged DNA, mitotic defects and integration of foreign DNA substantially increase
the risk of malignant progression [10].
Detection methods
A number of diagnostic methods are currently available to evaluate whether a tumour is
HPV+ve. These methods include both indirect as well as the direct methods; i.e. the
latter includes the detection of HPV genomic DNA (gDNA). Besides clinical examination,
current methods for the diagnosis of HPV status include tissue biopsy staining for p16
(indirect method). Biopsies may fail when tumours are too small to access or when they
are located in hidden anatomical sites [10]. Other methods include the detection of HPV
gDNA using PCR and in situ hybridization (ISH) as well as the detection of HPV viral
transcripts E6 and E7 by PCR.
p16 detection by IHC is widely used in cervical cancer cases for the detection of HPV and
it is being studied extensively in the field of HNC [12]. During immortalization of host
cells, the E7 protein binds to Rb, resulting in the compensatory overexpression of the
tumour suppressor gene p16 in HPV-infected tumour cells. Therefore, IHC detection of
p16 is considered as an indirect surrogate marker to determine the presence of HPV [11].
However, there are pitfalls associated with p16 IHC detection. A number of studies have
shown suboptimal specificity of IHC [10, 11]. As a consequence of the extreme
anatomical and biological heterogeneity in HNC, elevation of p16 by non-viral materials
may contribute to a considerable false positive rate [11]. Although it has been reported
that p16-positive patients have a better prognosis and increased radiosensitivity, it has
been advised that p16 detection by IHC alone cannot accurately identify HPV infection in
HNC [12].
Detection of HPV gDNA is a widely used method because of its high sensitivity and cost-
effectiveness. Common primers (MY09/MY11 and GP5/GP6) that target the L1 open
reading frame are used to detect wide-spectrum HPV genotypes [11]. However, standard
PCR primers do not allow detection of specific HPV genotypes [10]. In addition, the
target L1 region could also be deleted upon viral integration, which may affect sensitivity
of the test [10, 11]. Although, specific E6 and E7 primers have been designed and used
to overcome L1 deletion, this method still lacks the ability to distinguish stromal/tumour
and episomal/integrated DNA materials and is prone to contamination interference,
which undermines the clinical usefulness [11].
The HPV DNA ISH method is unique because of its high specificity and the ability to be
evaluated microscopically. The visible hybridization signals that precipitate within the
nuclei help distinguish integrated and episomal DNA [11]. It is noteworthy that the
presence of HPV DNA detected by ISH significantly correlates with p16 detection by IHC.
[10]. However, ISH methods carry lower sensitivity compared to its excellent specificity
[11]. The detection of HPV-16 viral transcripts E6 and E7 can highlight whether a patient
is suffering from persistent infection – information that is clinically more valuable [12].
However, because of the fragile nature of mRNA, formalin-fixed paraffin-embedded
(FFPE) specimens are often not ideal for RNA analysis and frozen fresh specimen are
required [12].
The detection of HPV-specific IgG in serum is a useful biomarker to determine previous
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consist of the major capsid protein HPV L1 [10]. The quadrivalent HPV 6/11/16/18
vaccine Gardasil™ was licensed by the FDA to prevent cervical, vaginal and vulvar
infections in women in 2006 and genital warts in men in 2009, followed by the licensing
of bivalent HPV 16/18 vaccine Cervarix™ (GlaxoSmithKline), in women in 2009 [14].
The benefits of HPV vaccination for the oral cavity include not only the biologically-
plausible direct effect on oral infections, but also the sequential oral infection reduction
following genital infection reduction, due to the sexually transmitted nature of HPV. To
date, there are only a few studies examining the effect of Gardasil on oral infection;
however, the results showed a promising outlook with high vaccine efficacy (as high as
93% in 4 years time, as recorded by randomized controlled trial in Costa Rica) [15] and
reduced viral prevalence (oral prevalence dropped to 1.4% from 9.3% in the 15–23 age
group in youth clinics in Sweden) [16].
Future outlook
As previously mentioned, HPV-related OPSCC involve a new segment of the population,
which is distinctively different to the traditional HNC patient cohort caused by excessive
smoking and drinking. This requires clinicians to conduct thorough cancer screening of
at-risk groups. Such screening programmes should pay particular attention to cervical
lymph nodes as some subtypes of HNC, especially OPSCC, involve hard-to-examine
areas for clinical visual examination.
As a result of the sexually transmitted nature of HPV, some studies have advocated
routine sexual behaviour education in clinical practice. However, this practice carries
inherent controversies of sexual harassment and confidentiality [17]. Public awareness
campaigns have been argued to be a more efficient preventative means in altering
patients’ behaviour. Studies have shown that many oral health practitioners have limited
knowledge with regards to HPV-related HNC and HPV vaccinations [17]. Professional
bodies and health authorities are required to address this knowledge gap by establishing
new clinical guidelines and using continuing educational methods, in order to effectively
control the rising trend of HPV-related HNC.
Conclusion
All current diagnostic methods require excision of tumour tissue and this can be
challenging when they are located in hidden sites. Efforts have been made globally to
develop a less invasive, more cost-effective and clinically-relevant test. Serology tests
that detect HPV-specific IgG have been shown to indicate viral presence and are linked
with prognostication; however, this method inherently lacks site specificity [10]. Oral
specimens, more specifically oral rinse, have shown promise in this field. Oral rinse
samples not only are non-invasive and cost-effective, the proximity of collection to the
area of interest ensures the localized sampling field. It is also important to note that
shedding of normal cells into the oral cavity/oral pharynx may interfere with and/or
decrease the HPV detection level [10]. OraRisk® HPV test, uses oral rinses for HPV
detection [10]. Translational collaborations between scientists and clinicians have
resulted in an assortment of tumour markers and diagnostic techniques for OPSCC.
However, these need to be tested in clinical trials to determine the cost-effectiveness.
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